ArticleJAMA oncology2018

Association of 70-Gene Signature Assay Findings With Physicians' Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay.

Michaela Tsai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.